about
Small RNA zippers lock miRNA molecules and block miRNA function in mammalian cells.Theranostic imaging of cancer.Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.Novel roles for LIX1L in promoting cancer cell proliferation through ROS1-mediated LIX1L phosphorylation.Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial.A direct quantification method for measuring plasma MicroRNAs identified potential biomarkers for detecting metastatic breast cancerTreatment of metastatic breast cancer: second line and beyond.Naturally occurring, tumor-specific, therapeutic proteins.Clinical overview of metronomic chemotherapy in breast cancer.Long noncoding RNAs in regulation of human breast cancer.Eribulin long-term response and rechallenge: report of two clinical cases.miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer.SPRY4-IT1: A novel oncogenic long non-coding RNA in human cancers.Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo.Systemic treatment with capecitabine as maintenance therapy in patients with recurring or metastatic breast cancer: experience in the Oncology Hospital, National Medical Center Siglo XXI, Mexican Social Security Institute.Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis.Metastasizing, Luciferase Transduced MAT‑Lu Rat Prostate Cancer Models: Follow up of Bolus and Metronomic Therapy with Doxorubicin as Model Drug.Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate.Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.New oral targeted therapies for metastatic breast cancer disrupt the traditional patients' management-A healthcare providers' view.
P2860
Q30833902-3577A230-175B-4C56-812B-6CDCD61D11B3Q33791349-3F9B6D5F-89EA-46C5-8076-A195EED8A325Q35584716-152DD469-57CC-46C6-ABFE-AFA5ABA2E825Q35624725-57FC9EFB-E23E-40DD-A9BD-8469BDCDC896Q35999416-9A6BC4B7-5967-40AB-B482-370BF09503EAQ37121774-E25095D0-EBA0-4A65-A898-E7510F5C7CB6Q37225420-E3A02419-C09A-4054-9C39-16E12262B752Q37802108-D1E073AC-0E4C-4A87-9624-719BC11FB622Q37869260-749E9AFC-1DA9-4ED6-A308-D6F4EC507E08Q38560651-803DDE53-8284-44E8-AFE6-E3D1CFD379B8Q38638146-F259099E-4636-4F91-BC19-ABC83A5CF88CQ38686613-7125EAB0-FB3D-4232-B3BB-100B803268F6Q38989276-3CE21DD1-70E1-44D9-AD63-D948449BF07EQ39398940-767E08A1-121D-4B8C-B1B9-B7595EE2DDCFQ41212817-49692189-5E16-47DC-AFED-CEB4D5A82673Q41346534-83E690D5-560E-4923-9D0D-22B9FF17CAD2Q42554491-70DE3574-1B48-44E0-907C-EE711A94FEB0Q42576985-1640801D-F1F5-4A42-9CBB-3274E7E60331Q43010569-470CD03B-ECEB-407F-A405-9835AA09510AQ43406910-0E855734-9D2E-4F0B-A552-49ADB78991E4Q48115704-24CE8BE1-99BC-4419-962A-0C916A468181
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Maintenance treatment in metastatic breast cancer.
@en
Maintenance treatment in metastatic breast cancer.
@nl
type
label
Maintenance treatment in metastatic breast cancer.
@en
Maintenance treatment in metastatic breast cancer.
@nl
prefLabel
Maintenance treatment in metastatic breast cancer.
@en
Maintenance treatment in metastatic breast cancer.
@nl
P2093
P2860
P1476
Maintenance treatment in metastatic breast cancer
@en
P2093
A Sánchez-Muñoz
Emilio Alba
N Ribelles
P2860
P304
P356
10.1586/14737140.8.12.1907
P577
2008-12-01T00:00:00Z